ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference
November 19 2020 - 7:21AM
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology
focused biopharmaceutical company developing innovative treatments
to transform the lives of patients, today announced Dr Carl Firth,
Chief Executive Officer of the company, will participate in a
fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare
Conference being held from 30 November to 3 December 2020.
A replay of the pre-recorded fireside chat will be available
from November 23, 2020 in the Investor Relations section of ASLAN’s
website at www.aslanpharma.com. The replay will be available for 30
days. ASLAN will be participating in 1x1 meetings on 30 November to
3 December 2020, meetings may be requested exclusively via Piper
Sandler.
Media and IR
contacts
Emma ThompsonSpurwing CommunicationsTel: +65 6751
2021Email: ASLAN@spurwingcomms.com |
Robert
UhlWestwicke PartnersTel: +1 858 356 5932 Email:
robert.uhl@westwicke.com |
|
|
About ASLAN PharmaceuticalsASLAN
Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology
focused biopharmaceutical company developing innovative treatments
to transform the lives of patients. Led by a senior management team
with extensive experience in global development and
commercialisation, ASLAN has a clinical portfolio comprised of a
first-in-class monoclonal therapy, ASLAN004, that is being
developed in atopic dermatitis and other immunology indications,
and ASLAN003, which it plans to develop for autoimmune disease. For
additional information please visit www.aslanpharma.com.
Forward
looking
statements
This release and the accompanying financial information, if any,
contains forward-looking statements. These statements are based on
the current beliefs and expectations of the management of ASLAN
Pharmaceuticals Limited and/or its affiliates (the "Company").
These forward-looking statements may include, but are not limited
to, statements regarding the Company’s business strategy and
clinical development plans; the Company’s plans to develop and
commercialise ASLAN004 and ASLAN003; the safety and efficacy of
ASLAN004 and ASLAN003; the Company’s plans and expected timing with
respect to clinical trials and clinical trial results for ASLAN004
and ASLAN003; the potential for ASLAN004 to deliver a
best-in-disease treatment for people with atopic dermatitis; the
potential for ASLAN003 to have a best in class profile as a potent
oral DHODH inhibitor targeting autoimmune indications; the
potential for ASLAN003 to be a treatment for COVID-19 and other
viral infections; and the scale of the unmet need in atopic
dermatitis. The Company’s estimates, projections and other
forward-looking statements are based on management's current
assumptions and expectations of future events and trends, which
affect or may affect the Company’s business, strategy, operations
or financial performance, and inherently involve significant known
and unknown risks and uncertainties. Actual results and the timing
of events could differ materially from those anticipated in such
forward-looking statements as a result of many risks and
uncertainties, which include, unexpected safety or efficacy data
observed during preclinical or clinical studies; clinical site
activation rates or clinical trial enrolment rates that are lower
than expected; the impact of the COVID-19 pandemic on the Company’s
business and the global economy; general market conditions; changes
in the competitive landscape; and the Company’s ability to obtain
sufficient financing to fund its strategic and clinical development
plans. Other factors that may cause actual results to differ from
those expressed or implied in such forward-looking statements are
described in the Company’s US Securities and Exchange Commission
filings and reports (Commission File No. 001-38475), including the
Company’s Annual Report on Form 20-F filed with the US Securities
and Exchange Commission on April 16, 2020.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Sep 2023 to Sep 2024